Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Bioactive properties and clinical safety of a novel milk protein peptide.

Kreider RB, Iosia M, Cooke M, Hudson G, Rasmussen C, Chen H, Mollstedt O, Tsai MH.

Nutr J. 2011 Sep 26;10:99. doi: 10.1186/1475-2891-10-99.

PMID:
21943352
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.

McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM.

Mol Cancer Ther. 2004 Sep;3(9):1041-8.

PMID:
15367698
[PubMed - indexed for MEDLINE]
Free Article
3.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

PMID:
12684431
[PubMed - indexed for MEDLINE]
Free Article
4.

A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.

Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.

Invest New Drugs. 2012 Apr;30(2):490-507. doi: 10.1007/s10637-010-9577-1. Epub 2010 Nov 16.

PMID:
21080210
[PubMed - indexed for MEDLINE]
5.

Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.

Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T, Langley RR, Fan D, Kim SJ, Fidler IJ.

Neoplasia. 2007 Dec;9(12):1066-77.

PMID:
18084614
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.

Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137.

PMID:
20039326
[PubMed - indexed for MEDLINE]
7.

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.

PMID:
17308046
[PubMed - indexed for MEDLINE]
Free Article
8.

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.

J Clin Oncol. 2012 Apr 1;30(10):1114-21. doi: 10.1200/JCO.2011.36.1709. Epub 2012 Feb 27.

PMID:
22370318
[PubMed - indexed for MEDLINE]
9.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

PMID:
12684433
[PubMed - indexed for MEDLINE]
Free Article
10.

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.

Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M.

Cancer Biol Ther. 2010 Apr 15;9(8):592-603. Epub 2010 Apr 4.

PMID:
20139705
[PubMed - indexed for MEDLINE]
Free Article
11.

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K.

Anticancer Drugs. 2006 Aug;17(7):783-95.

PMID:
16926628
[PubMed - indexed for MEDLINE]
12.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
13.

Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP.

J Thorac Oncol. 2012 Mar;7(3):485-95. doi: 10.1097/JTO.0b013e31824177ea.

PMID:
22258476
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
15.

Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.

Telliez A, Desroses M, Pommery N, Briand O, Farce A, Laconde G, Lemoine A, Depreux P, Hénichart JP.

ChemMedChem. 2007 Mar;2(3):318-32.

PMID:
17206733
[PubMed - indexed for MEDLINE]
16.

Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.

Suzuki T, Fujii A, Ohya J, Amano Y, Kitano Y, Abe D, Nakamura H.

Cancer Sci. 2007 Dec;98(12):1977-84. Epub 2007 Sep 18.

PMID:
17888033
[PubMed - indexed for MEDLINE]
17.

Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.

Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN.

Mol Cancer Ther. 2006 Nov;5(11):2696-705.

PMID:
17121916
[PubMed - indexed for MEDLINE]
Free Article
18.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
19.

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.

Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.

Clin Cancer Res. 2006 Mar 1;12(5):1630-8.

PMID:
16533791
[PubMed - indexed for MEDLINE]
Free Article
20.

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2001 May;7(5):1459-65.

PMID:
11350918
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk